We are honored to be ranked in the Top 5 of CB Insights’ Top 50 Venture Investors in France, among over 1000 active investors who made the list. In today’s market, standing out is not just about volume of deals, it is about building durable, high-performing portfolios grounded in partnership, scientific rigour and a long-term view. Congratulations to all our fellow investors. We remain committed to backing science-led innovation that changes lives.
Sofinnova Partners
Services financiers
Paris, Ile-de-France 34 187 abonnés
Sofinnova Partners is a leading European VC firm in life sciences, specializing in healthcare and sustainability.
À propos
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €4 billion under management. For more information, please visit: www.sofinnovapartners.com
- Site web
-
http://sofinnovapartners.com/
Lien externe pour Sofinnova Partners
- Secteur
- Services financiers
- Taille de l’entreprise
- 51-200 employés
- Siège social
- Paris, Ile-de-France
- Type
- Partenariat
- Fondée en
- 1972
- Domaines
- Pharmaceutical / biotech, Medical devices, Industrial Biotechnology, Sustainability, Biopharma, Medtech, Venture Capital, Private Equity, Biotech et Biotechnology
Lieux
-
Principal
Obtenir l’itinéraire
7-11, Boulevard Haussmann
75009 Paris, Ile-de-France, FR
-
Obtenir l’itinéraire
1 Pancras Square
N1C 4AG King's Cross, London, GB
-
Obtenir l’itinéraire
Via Borgogna, 5
20122 Milan, Lombardy, IT
Employés chez Sofinnova Partners
Nouvelles
-
Sofinnova’s Joško Bobanović in the latest European Biotechnology - Life Science and Industry Magazine (EBM) explains why scaling industrial biotech demands more than capital. Strategic exits, patient capital and infrastructure investment are critical to unlocking the sector's full potential. Explore how Sofinnova’s industrial biotech strategy is driving impact at scale.
-
-
Proof that early conviction can lead to real clinical and strategic outcomes: CinCor Pharma, Inc.’s lead candidate, baxdrostat, positive Phase 3 results are more than strong data. When CinCor Pharma, Inc. was acquired by AstraZeneca in early 2023, it marked a milestone moment for Sofinnova Partners and our commitment to supporting pioneers at the intersection of biology and data. Marc de Garidel, who led CinCor’s journey, now heads Abivax. It’s a reminder of what drives us at Sofinnova: science backed by exceptional people. Leaders like Marc shape the long-term impact of innovation. The journey from scientific concept to patient impact is complex, but moments like these reaffirm our long-term partnership. Read the full BioPharma Dive article for more.
-
-
Sofinnova Partners portfolio company AAVantgarde Bio receives FDA clearance to initiate clinical trial for Stargardt disease. The CELESTE Phase 1/2 trial will evaluate AAVB-039, a new gene therapy developed to treat Stargardt disease, a rare genetic eye disorder that causes vision loss in young people. This is an important milestone for patients living with Stargardt disease and a strong signal of European science shaping the future of global health innovation. Link to press release in the comments.
✨ We are thrilled to announce that the #FDA has cleared our IND application for AAVB-039, the best-in-class dual AAV intein gene therapy for Stargardt disease showing the highest quantified ABCA4 protein expression in relevant large animal models. This is a pivotal moment for our team and for patients living with #StargardtDisease — bringing us one step closer to delivering a much-needed treatment where none currently exists. 🎉 Congratulations and thank you to the AAVantgarde team for the hard work put into this submission! 👇 Find more about our AAVB-039 program, able to address all Stargardt patients independently of their ABCA4 mutation: https://lnkd.in/dyEvcXKZ #StargardtDisease #GeneTherapy #Ophthalmology #IRDs #RareDisease #VisionRestoration #TIGEM #FondazioneTelethon
-
Micropep Technologies welcomes Georg Goeres as CEO, bringing 20+ years of global agtech and biologicals leadership. The company enters a pivotal phase of commercial growth, with its first biofungicide advancing through regulatory stages and its Krisalix™ platform gaining traction. Sofinnova Partners has backed Micropep from scientific breakthrough to platform scale, and we thank Thomas LAURENT for his outstanding leadership in laying the foundation for what’s next. Wishing Georg and the team every success in this new chapter. 👏🏼
🌱 New Leadership for the Next Chapter at Micropep We’re excited to welcome Georg Goeres as our new CEO Georg brings over two decades of global leadership in agriculture and biologicals, most recently heading the Biologicals Business Unit at Indigo Agriculture. His deep commercial expertise and passion for sustainable innovation make him the ideal leader to guide Micropep into its next phase of growth. As we move toward commercialization of our first biofungicide and continue to expand the capabilities of our Krisalix™ discovery platform, Georg’s appointment marks a pivotal moment in our journey. We also extend our heartfelt thanks to Thomas LAURENT, Micropep’s founder and outgoing CEO, whose vision and leadership transformed a groundbreaking academic discovery into a global deeptech platform. Thomas will continue to support the company as a strategic advisor. The future of crop protection is being rewritten—and we’re just getting started. 🔗 https://lnkd.in/gF-DiXHz #Micropep #Leadership #AgTech #Biologicals #Innovation #CropProtection
-
Sofinnova Partners portfolio company Bioptimus just welcomed Julie Gerardi as its first Chief Commercial Officer, a pivotal step as the company scales its commercial and strategic ambitions globally. With over 25 years of experience scaling life sciences ventures, from early-stage biotech to global pharma, Julie’s arrival marks an important step in Bioptimus’s growth. Backed by a strong scientific foundation and now the leadership to take it to market, Bioptimus is shaping the next generation of foundation models for biology. Join us in congratulating Julie Gerardi and the entire team at Bioptimus on this exciting new chapter. 👏
🎉 We're thrilled to welcome Julie Gerardi as Bioptimus's first Chief Commercial Officer! A biotech industry veteran with 25+ years of experience, Julie has been part of building pioneering life science businesses across the most exciting and fast-growing biotech startups and Fortune 500 companies, like Parse, Tempus, Definiens and Astra Zeneca. Julie will spearhead our mission to transform how biological research and drug development are conducted, driving strategic partnerships and commercial initiatives that will bring the power of foundation models to the global life sciences community. Welcome to the team, Julie! 🧬 #Bioptimus #AIforBiology #FoundationModels #Biotech
-
-
Sofinnova Partners a republié ceci
We are proud to announce that we have received IND clearance from the FDA for PS-002, our lead program initially targeting IgA nephropathy (IgAN). IgAN is a rare, chronic autoimmune kidney disease with limited treatment options and significant unmet medical need and this important milestone will enable us to initiate a Phase I/II clinical trial later this year. PS-002 is designed to target the underlying cause of kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. This approach allows us to go beyond systemic treatments, delivering kidney-specific therapies that offer durable, disease-modifying benefits for patients. Looking ahead, we are excited to building on this momentum as we pursue our ambition to revolutionise kidney disease treatment. For more information, read the full press release here https://lnkd.in/egejWK9U #IND #ClinicalTrial #KidneyDisease #Precisionnephrology
-
A major milestone for CorWave, a Sofinnova Partners portfolio company, which has just implanted its bio-inspired cardiac pump in a patient for the very first time. This life-saving innovation mimics the natural rhythm of the human heart. A standout example of deeptech innovation, delivering real-world impact for patients. Founded by the team behind our medtech accelerator, CorWave has grown with the backing of Sofinnova and other top-tier investors over the years. 👏 Bravo to the CorWave team!👏
𝐍𝐨𝐮𝐬 𝐲 𝐬𝐨𝐦𝐦𝐞𝐬 ! Première mondiale : après plus de 10 ans de R&D, une pompe CorWave a été implantée à la pointe du cœur d’un patient souffrant d’insuffisance cardiaque sévère… et le « fait revivre ». Michael, 67 ans, le premier patient CorWave, va très bien cf 📺⤵️. Il a pu quitter l’hôpital St Vincent's Health Australia à Sydney, où une équipe médicale d’exception a réalisé l’opération et assuré le suivi post-opératoire. L’intervention est un succès : nous avons atteint le « primary endpoint » ou « critère de jugement principal ». Par ailleurs, la pompe permet de maintenir son pouls. Les battements du cœur 💗 — tac boum tac boum — animent ses artères, la valve aortique s’ouvre. Cela pourrait permettre de réduire les complications associées aux assistances circulatoires actuelles. La dernière rupture technologique majeure dans notre secteur remonte à novembre 1998, avec la première implantation d’une pompe de longue durée à débit continu, sous l’impulsion d’un ingénieur de la NASA 🚀 et d’un chirurgien texan pionnier 🤠. Ces technologies rotatives ont, depuis, permis d’améliorer considérablement la survie. Mais, en supprimant le pouls des patients et en dérégulant leur système cardiovasculaire, elles favorisent aussi l’apparition de complications, ce à quoi s'attaque CorWave. C’est une vive émotion de voir Michael décrire la disparition des symptômes de l’insuffisance cardiaque avancée. Cela récompense des années d’efforts, menés avec une persévérance hors norme par les équipes de CorWave, qui ont conduit des recherches à la frontière de la connaissance 🧑🚀, travaillé la matière à l’échelle du micron avec une précision redoutable 👩🏭 pour concevoir et fabriquer une pompe d'un nouveau genre inspirée de la nage ondulatoire des animaux aquatiques. Des ingénieurs brillants, des talents industriels venus des quatre coins du monde ont convergé vers la région parisienne. L’esprit pionnier anglo-saxon s’est mêlé à notre panache hexagonal — impossible n’est pas français — pour mener à bien ce projet « moonshot » 🌔. Cette prouesse est une victoire de l’équipe France 🇫🇷 et de l’équipe Europe 🇪🇺. Depuis des décennies, notre écosystème d’innovation se développe et mûrit, soutenu par les pouvoirs publics de tous bords et avec une nette accélération ces dernières années, notamment grâce à Bpifrance et à l’EIC Fund, voulu par notre Président de la République dans son discours de la Sorbonne. Je suis convaincu que cela permettra à des inventions made in Europe de donner naissance à de nombreuses entreprises innovantes à impact mondial. C’est, en tout cas, ce que nous tâcherons de faire avec CorWave et restons concentrés sur nos essais cliniques dans les cadre desquels nous devons démontrer la sécurité et la performance de notre dispositif. Plusieurs centaines de personnes ont rendu cela possible, je vais oublier trop de noms mais retrouvez en commentaires les cliniciens, les investisseurs et soutiens publics qui ont été déterminants.
-
Welcome onboard, Actithera! The company joins Sofinnova Partners' portfolio following a $75.5 million oversubscribed Series A round. The financing will enable Actithera to advance its lead fibroblast activation protein (FAP)-targeted radioligand into clinical development across multiple indications. It will also support the continued growth of the company’s proprietary discovery platform, which integrates rational drug design with radiochemistry to develop next-generation radioligand therapies (RLTs) that address the current key limitations in the field. Learn more about Actithera and their Series A in the press release in the comments.
-
-
Sofinnova Partners a republié ceci
📣 Actithera closes $75.5M oversubscribed Series A! 📣 We are proud to announce the successful close of our $75.5 million Series A financing, co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners and 4BIO Capital, with participation from Bioqube Ventures, Innovestor, Investinor, Surveyor Capital and second founding investor, Arkin Capital. Led by our founder and drug discovery expert, Dr. Andreas Goutopoulos, Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). This significant financing will allow us to: 🧪 Advance our FAP-targeting lead candidate into clinical development 🔬Continue building our proprietary RLT discovery platform and preclinical pipeline Actithera’s discovery platform combines rational drug design with radiochemistry to create novel small molecule radioligands that overcome current limitations in radiopharmaceutical development. Our FAP-directed RLT candidate offers best-in-class potential with its optimal pharmacokinetic profile and tumor specificity. We would like to thank our investors for their continued support and belief in our mission as we progress towards the clinic. 👉 Read the full announcement here: https://lnkd.in/e55Wm6eZ #Biotech #RadioligandTherapies #Oncology #RLTs #LifeSciences
-